MCRBHealthcareMicro-Cap
Seres Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Seres Therapeutics, Inc. (MCRB), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are MCRB insiders buying or selling?
Seres Therapeutics, Inc. insiders reported 2 open-market buys ($47.5M) and 83 sells ($5.8M) across 85 Form 4 filings — a net buying position of $41.7M.
Source: SEC EDGAR Form 4
Key Statistics (as of May 19, 2026)
Total Form 4 filings
85
SEC EDGAR
Insider filers
14
Insider buys (2)
$47.5M
Insider sells (83)
$5.8M
Insider sentiment
Net buyingNet insider flow of $41.7M in net buying.
Recent MCRB insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 19, 2026 | Thomas Desrosier | EVP and Chief Legal Officer | Sale | 79 | $7.53 | $594.87 |
| May 19, 2026 | Eric D. Shaff | Director | Sale | 259 | $7.53 | $2.0K |
| May 19, 2026 | Matthew R Henn | Chief Scientific Officer and EVP | Sale | 77 | $7.53 | $579.81 |
| May 19, 2026 | Kelly Brady | Chief Operating Officer, EVP | Sale | 59 | $7.53 | $444.27 |
| Feb 18, 2026 | Eric D. Shaff | Director | Sale | 259 | $8.47 | $2.2K |
| Feb 18, 2026 | Teresa L. Young | EVP, Chief Commercial & Strategy Officer | Sale | 75 | $8.47 | $635.25 |
| Feb 18, 2026 | Thomas Desrosier | Chief Legal Officer, EVP, Co-Chief Executive Officer, and Co-President | Sale | 78 | $8.47 | $660.66 |
| Feb 18, 2026 | Matthew R Henn | Chief Scientific Officer and EVP | Sale | 89 | $8.47 | $753.83 |
| Nov 18, 2025 | Teresa L. Young | EVP, Chief Commercial & Strategy Officer | Sale | 1.0K | $17.30 | $18.0K |
| Nov 18, 2025 | Eric D. Shaff | Director | Sale | 217 | $17.30 | $3.8K |
| Nov 18, 2025 | Thomas Desrosier | Chief Legal Officer, EVP, Co-Chief Executive Officer, and Co-President | Sale | 76 | $17.30 | $1.3K |
| Nov 18, 2025 | Matthew R Henn | Chief Scientific Officer and EVP | Sale | 1.3K | $17.30 | $21.7K |
| Aug 19, 2025 | Eric D. Shaff | Director | Sale | 217 | $16.65 | $3.6K |
| Aug 19, 2025 | Thomas Desrosier | Chief Legal Officer, EVP, Co-Chief Executive Officer, and Co-President | Sale | 76 | $16.65 | $1.3K |
| Aug 19, 2025 | Matthew R Henn | Chief Scientific Officer and EVP | Sale | 73 | $16.65 | $1.2K |
| Aug 19, 2025 | Teresa L. Young | EVP, Chief Commercial & Strategy Officer | Sale | 59 | $16.65 | $982.35 |
| May 19, 2025 | Teresa L. Young | EVP, Chief Commercial & Strategy Officer | Sale | 63 | $7.28 | $458.64 |
| May 19, 2025 | Eric D. Shaff | CEO and President | Sale | 220 | $7.28 | $1.6K |
| May 19, 2025 | Thomas Desrosier | Chief Legal Officer and EVP | Sale | 79 | $7.28 | $575.12 |
| May 19, 2025 | Matthew R Henn | Chief Scientific Officer and EVP | Sale | 77 | $7.28 | $560.56 |
| Feb 20, 2025 | Teresa L. Young | EVP, Chief Commercial & Strategy Officer | Sale | 3.3K | $0.81 | $2.7K |
| Feb 20, 2025 | Matthew R Henn | Chief Scientific Officer and EVP | Sale | 4.0K | $0.81 | $3.2K |
| Feb 20, 2025 | Eric D. Shaff | CEO and President | Sale | 12.7K | $0.81 | $10.3K |
| Feb 20, 2025 | Thomas Desrosier | Chief Legal Officer and EVP | Sale | 4.3K | $0.81 | $3.5K |
| Feb 20, 2025 | Moltke Lisa Von | Executive Vice President and Chief Medical Officer | Sale | 4.4K | $0.81 | $3.6K |
Showing the 25 most recent of 85 Form 4 filings for Seres Therapeutics, Inc..
Most active MCRB insiders
- Eric D. Shaff13 filings
- Matthew R Henn13 filings
- Thomas Desrosier13 filings
- Teresa L. Young12 filings
- Roger Pomerantz8 filings
Ask anything about MCRB insider activity
Use Trabud's AI agent to query Seres Therapeutics, Inc.'s Form 4 history in plain English — "Show me MCRB CEO purchases this year" or compare it against any other ticker.
Open the AI agentMCRB insider trading FAQ
Are Seres Therapeutics, Inc. insiders buying or selling?
Across 85 SEC Form 4 filings, Seres Therapeutics, Inc. (MCRB) insiders reported 2 open-market purchases totaling $47.5M and 83 sales totaling $5.8M. That is a net buying position of $41.7M.
How many insiders trade MCRB stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Seres Therapeutics, Inc.. The most recent filing was accepted on May 19, 2026.
Where does Trabud get MCRB insider trading data?
All MCRB insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.